Drugs & Therapy Perspectives

, Volume 35, Issue 4, pp 181–184 | Cite as

Tamsulosin in urology: beyond benign prostatic hyperplasia

  • G. G. Laxman PrabhuEmail author
  • Hiren PrajapatiEmail author
  • Alok Chaturvedi
  • Nilanj Dave
  • Amit B. Jain
Review Article


Tamsulosin, a third-generation uroselective α1A adrenergic receptor blocker (antagonist), has been approved for the treatment of signs and symptoms of benign prostatic hyperplasia for more than two decades. Apart from this approved use, more recent evidence has been published regarding the off-label use of tamsulosin in various other urological conditions. However, further research is needed regarding the use of tamsulosin in these indications. This review highlights the possible therapeutic uses of tamsulosin for the management of various urological conditions.


Compliance with ethical standards

Conflict of interest

Hiren Prajapati, Alok Chaturvedi, Nilanj Dave and Amit B. Jain are salaried employees of Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat, India.


  1. 1.
    Noble AJ, Chess-Williams R, Couldwell C, et al. The effects of tamsulosin, a high affinity antagonist at functional α-1A and α-1D adrenoceptor subtypes. Br J Pharmacol. 1997;120:231–8.CrossRefGoogle Scholar
  2. 2.
    Lee M. Tamsulosin for the treatment of benign prostatic hypertrophy. Ann Pharmacother. 2000;34(2):188–99.CrossRefGoogle Scholar
  3. 3.
    Flomax® label. Package insert. Accessed 11 Nov 2018.
  4. 4.
    Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 2012;367:248–57Google Scholar
  5. 5.
    Dunn CJ, Matheson A, Faulds DM. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging. 2002;19(2):135–61.CrossRefGoogle Scholar
  6. 6.
    Lewis W. Off-label use tamsulosin in the presence of uncomplicated radiographically proven distal urolithiasis [thesis]. Paper no. 162. Hillsboro: School of Physician Assistant Studies; 2009. p. 8–34.Google Scholar
  7. 7.
    Fan B, Yang D, Wang J, et al. Can tamsulosin facilitate expulsion of ureteral stones? A meta-analysis of randomized controlled trials. Int J Urol. 2013;20(8):818–30.CrossRefGoogle Scholar
  8. 8.
    Nuraj P, Hyseni N. The role of the tamsulosin in the medical expulsion therapy for distal ureteral stones. Med Arch. 2017;71(2):137–40.CrossRefGoogle Scholar
  9. 9.
    Wang RC, Smith-Bindman R, Whitaker E, et al. Effect of tamsulosin on stone passage for ureteral stones: a systematic review and meta-analysis. Ann Emerg Med. 2017;69(3):353–361.e3.CrossRefGoogle Scholar
  10. 10.
    Rivard R. Tamsulosin: ureteral stones (distal). Hosp Pharm. 2015;50(1):31–3.CrossRefGoogle Scholar
  11. 11.
    Madani AH, Aval HB, Mokhtari G, et al. Effectiveness of tamsulosin in prevention of post-operative urinary retention: a randomized double-blind placebo-controlled study. Int Braz J Urol. 2014;40(1):30–6.CrossRefGoogle Scholar
  12. 12.
    Altarac S. Alpha-adrenergic blockers as a support in the treatment of acute urinary retention [in Croatian]. Lijec Vjesn. 2006;128(7–8):233–7.Google Scholar
  13. 13.
    Agrawal MS, Yadav A, Yadav H, et al. A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian J Urol. 2009;25(4):474–8.CrossRefGoogle Scholar
  14. 14.
    Anothaisintawee T, Attia J, Nickel JC, et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA. 2011;305:78–86.CrossRefGoogle Scholar
  15. 15.
    Nickel JC, Narayan P, McKay J, et al. Treatment of chronic prostatitis /chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol. 2004;171(4):1594–7.CrossRefGoogle Scholar
  16. 16.
    Zhang T, Wu H, Liu S, et al. Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients. Int Urol Nephrol. 2017;49(7):1111–7.CrossRefGoogle Scholar
  17. 17.
    Liucheng D, Zhongqing W. Tamsulosin application for the treatment of advanced prostate cancer accompany with bladder outlet obstruction [abstract no. 642]. Accessed 27 Nov 2018.
  18. 18.
    Tubaro A, De Nunzio C, Mariani S, et al. Reduction of prostate-specific antigen after tamsulosin treatment in patients with elevated prostate-specific antigen and lower urinary tract symptoms associated with low incidence of prostate cancer at biopsy. Urology. 2010;76(2):436–41.CrossRefGoogle Scholar
  19. 19.
    Merrick GS, Butler WM, Wallner KE, et al. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology. 2002;60(4):650–5.CrossRefGoogle Scholar
  20. 20.
    Djavan B, Shariat S, Fakhari M, et al. Neoadjuvant and adjuvant α-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial. Urology. 1999;53(2):251–9.CrossRefGoogle Scholar
  21. 21.
    Abrams P, Amarenco G, Bakke A, et al. European Tamsulosin Neurogenic Lower Urinary Tract Dysfunction Study Group. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol 2003;170(4 Pt 1):1242–51.Google Scholar
  22. 22.
    Kakizaki H, Ameda K, Kobayashi S, et al. Urodynamic effects of α1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder. Int J Urol. 2003;10(11):576–81.CrossRefGoogle Scholar
  23. 23.
    Moussa AS, Ibrahim RM, Abdelbary AM, et al. Tamsulosin to relieve JJ stent related discomfort: a prospective randomized placebo controlled crossover study. J Urol Res. 2017;4(4):1092.Google Scholar
  24. 24.
    Navanimitkul N, Lojanapiwat B. Efficacy of tamsulosin 0.4 mg/day in relieving double-J stent-related symptoms: a randomized controlled study. J Int Med Res. 2010;38(4):1436–41.Google Scholar
  25. 25.
    Aggarwal SP, Priyadarshi S, Tomar V, et al. A randomized controlled trial to compare the safety and efficacy of tadalafil and tamsulosin in relieving double J stent related symptoms. Adv Urol. 2015;592175.
  26. 26.
    Meyer LE, Brown JN. Tamsulosin for voiding dysfunction in women. Int Urol Nephrol. 2012;44(6):1649–56.CrossRefGoogle Scholar
  27. 27.
    Minardi D, Pellegrinelli F, Conti A, et al. α1-blockers for the treatment of recurrent urinary tract infections in women with dysfunctional voiding: a prospective randomized study. Int J Urol. 2015;22(1):115–21.CrossRefGoogle Scholar
  28. 28.
    Murdoch FE, Goldberg E. Male contraception: another holy grail. Bioorg Med Chem Lett. 2014;24(2):419–24.CrossRefGoogle Scholar
  29. 29.
    Grasso M, Fortuna F, Lania C, et al. Ejaculatory disorders and α1-adrenoceptor antagonists therapy: clinical and experimental researches. J Transl Med. 2006;4:31. Scholar
  30. 30.
    Bhat G, Bhat A. BKP 02: prospective double blind randomised study to evaluate the efficacy of siliodosin 8 mg as on demand, reversible, male oral contraceptive. Indian J Urol. 2018;34(Suppl 1):S7–72.Google Scholar
  31. 31.
    Chiles KA. Musings on male dysorgasmia. J Sex Med. 2017;14(4):489–90.CrossRefGoogle Scholar
  32. 32.
    Barnas J, Parker M, Guhring P, et al. The utility of tamsulosin in the management of orgasm-associated pain: a pilot analysis. Eur Urol. 2005;47(3):361–5.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of UrologyKMC HospitalMangaloreIndia
  2. 2.Department of Medical AffairsIntas Pharmaceuticals LimitedAhmedabadIndia

Personalised recommendations